Finding Maximum Tolerated Dose in Phase I Oncology Clinical Trials with Bayesian Methods

被引：0
|
作者：
Sapi, Johanna [1 ,2 ]
机构：
[1] Obuda Univ, Biomat & Appl Artificial Intelligence Inst, John von Neumann Fac Informat, Becsi Ut 96-B, H-1034 Budapest, Hungary
[2] Obuda Univ, Univ Res & Innovat Ctr, Physiol Controls Res Ctr, Becsi Ut 96-B, H-1034 Budapest, Hungary
来源：
ACTA POLYTECHNICA HUNGARICA | 2024年 / 21卷 / 06期
关键词：
maximum tolerated dose (MTD); dose-limiting toxicity (DLT); Continual Reassessment Method (CRM); Time-To-Event Continual Reassessment Method (TITE- CRM); copula regression model; logistic regression model; delayed toxicities; late-onset toxicity model; CONTINUAL REASSESSMENT; DESIGN; TOXICITY; COMBINATIONS; AGENT;
D O I：
暂无
中图分类号：
T [工业技术];
学科分类号：
08 ;
摘要：
Maximum tolerated dose (MTD) is a maximal amount of drug or radiation resulting relatively acceptable dose-limiting toxicity (DLT). Accurate value of MTD should be found in Phase I trials in order to create the possibility to conduct successful Phase II (pilot efficacy and safety evaluation) and Phase III (comparative efficacy) trials. The aim of this paper is to review the difficulties of the dose-finding methods including multi-agent problems and late-onset toxicities, and to discuss Bayesian adaptive dose-finding methods which can handle these issues.
引用
收藏
页码：129 / 145
页数：17
相关论文
共 50 条
  • [21] Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation
    Li, Yisheng
    Bekele, B. Nebiyou
    Ji, Yuan
    Cook, John D.
    STATISTICS IN MEDICINE, 2008, 27 (24) : 4895 - 4913
  • [22] A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity
    Whitehead, John
    Thygesen, Helene
    Whitehead, Anne
    STATISTICS IN MEDICINE, 2010, 29 (17) : 1808 - 1824
  • [23] Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations
    Ursino, Moreno
    Zohar, Sarah
    Lentz, Frederike
    Alberti, Corinne
    Friede, Tim
    Stallard, Nigel
    Comets, Emmanuelle
    BIOMETRICAL JOURNAL, 2017, 59 (04) : 804 - 825
  • [24] Bayesian optimal interval design for phase I oncology clinical trials
    Fellman, Bryan M.
    Yuan, Ying
    STATA JOURNAL, 2015, 15 (01): : 110 - 120
  • [25] BAYESIAN METHODS FOR PHASE-I CLINICAL-TRIALS
    GATSONIS, C
    GREENHOUSE, JB
    STATISTICS IN MEDICINE, 1992, 11 (10) : 1377 - 1389
  • [26] Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy
    Liu, Rachael
    Lin, Jianchang
    Li, Pin
    CONTEMPORARY CLINICAL TRIALS, 2020, 96
  • [27] Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios
    Yin, Guosheng
    Li, Yisheng
    Ji, Yuan
    BIOMETRICS, 2006, 62 (03) : 777 - 784
  • [28] Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials
    Lin, Ruitao
    Yin, Guosheng
    Shi, Haolun
    BIOSTATISTICS, 2023, 24 (02) : 277 - 294
  • [29] Patient-specific dose finding in phase I clinical trials
    Moni, Md. Moniruzzaman
    Alam, M. Iftakhar
    JOURNAL OF APPLIED STATISTICS, 2018, 45 (14) : 2607 - 2618
  • [30] MODEL-GUIDED DETERMINATION OF MAXIMUM TOLERATED DOSE IN PHASE-I CLINICAL-TRIALS - EVIDENCE FOR INCREASED PRECISION
    MICK, R
    RATAIN, MJ
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) : 217 - 223
12345